RNAZ

TransCode Therapeutics, Inc.

1.06 USD
+0.04 (+3.92%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

TransCode Therapeutics, Inc. stock is down -40.78% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 June’s closed higher than May. 100% of analysts rate it a buy.

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. engages in the development and commercialization of drugs and diagnostics. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company was incorporated in 2016 and is based in Boston, Massachusetts.